A citation-based method for searching scientific literature

Patrick M O'Neil, Andreas L Birkenfeld, Barbara McGowan, Ofri Mosenzon, Sue D Pedersen, Sean Wharton, Charlotte Giwercman Carson, Cecilie Heerdegen Jepsen, Maria Kabisch, John P H Wilding. Lancet 2018
Times Cited: 214







List of co-cited articles
852 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
786
38

Once-Weekly Semaglutide in Adults with Overweight or Obesity.
John P H Wilding, Rachel L Batterham, Salvatore Calanna, Melanie Davies, Luc F Van Gaal, Ildiko Lingvay, Barbara M McGowan, Julio Rosenstock, Marie T D Tran, Thomas A Wadden,[...]. N Engl J Med 2021
267
31

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
26

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Melanie J Davies, Richard Bergenstal, Bruce Bode, Robert F Kushner, Andrew Lewin, Trine Vang Skjøth, Arne Haahr Andreasen, Christine Bjørn Jensen, Ralph A DeFronzo. JAMA 2015
390
23

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Melanie Davies, Louise Færch, Ole K Jeppesen, Arash Pakseresht, Sue D Pedersen, Leigh Perreault, Julio Rosenstock, Iichiro Shimomura, Adie Viljoen, Thomas A Wadden,[...]. Lancet 2021
82
26

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
21

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.
Robert F Kushner, Salvatore Calanna, Melanie Davies, Dror Dicker, W Timothy Garvey, Bryan Goldman, Ildiko Lingvay, Mette Thomsen, Thomas A Wadden, Sean Wharton,[...]. Obesity (Silver Spring) 2020
56
37

Semaglutide lowers body weight in rodents via distributed neural pathways.
Sanaz Gabery, Casper G Salinas, Sarah J Paulsen, Jonas Ahnfelt-Rønne, Tomas Alanentalo, Arian F Baquero, Stephen T Buckley, Erzsébet Farkas, Csaba Fekete, Klaus S Frederiksen,[...]. JCI Insight 2020
84
23

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
Thomas A Wadden, Timothy S Bailey, Liana K Billings, Melanie Davies, Juan P Frias, Anna Koroleva, Ildiko Lingvay, Patrick M O'Neil, Domenica M Rubino, Dorthe Skovgaard,[...]. JAMA 2021
83
24


Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
293
19

The Discovery and Development of Liraglutide and Semaglutide.
Lotte Bjerre Knudsen, Jesper Lau. Front Endocrinol (Lausanne) 2019
157
17

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Domenica Rubino, Niclas Abrahamsson, Melanie Davies, Dan Hesse, Frank L Greenway, Camilla Jensen, Ildiko Lingvay, Ofri Mosenzon, Julio Rosenstock, Miguel A Rubio,[...]. JAMA 2021
67
25

Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
John Blundell, Graham Finlayson, Mads Axelsen, Anne Flint, Catherine Gibbons, Trine Kvist, Julie B Hjerpsted. Diabetes Obes Metab 2017
119
16

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Richard Pratley, Aslam Amod, Søren Tetens Hoff, Takashi Kadowaki, Ildiko Lingvay, Michael Nauck, Karen Boje Pedersen, Trine Saugstrup, Juris J Meier. Lancet 2019
169
15

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
W Timothy Garvey, Jeffrey I Mechanick, Elise M Brett, Alan J Garber, Daniel L Hurley, Ania M Jastreboff, Karl Nadolsky, Rachel Pessah-Pollack, Raymond Plodkowski. Endocr Pract 2016
451
14

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
Carel W le Roux, Arne Astrup, Ken Fujioka, Frank Greenway, David C W Lau, Luc Van Gaal, Rafael Violante Ortiz, John P H Wilding, Trine V Skjøth, Linda Shapiro Manning,[...]. Lancet 2017
278
14

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Richard E Pratley, Vanita R Aroda, Ildiko Lingvay, Jörg Lüdemann, Camilla Andreassen, Andrea Navarria, Adie Viljoen. Lancet Diabetes Endocrinol 2018
248
14

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Mansoor Husain, Andreas L Birkenfeld, Morten Donsmark, Kathleen Dungan, Freddy G Eliaschewitz, Denise R Franco, Ole K Jeppesen, Ildiko Lingvay, Ofri Mosenzon, Sue D Pedersen,[...]. N Engl J Med 2019
500
14

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Frank L Greenway, Ken Fujioka, Raymond A Plodkowski, Sunder Mudaliar, Maria Guttadauria, Janelle Erickson, Dennis D Kim, Eduardo Dunayevich. Lancet 2010
460
13

European Guidelines for Obesity Management in Adults.
Volkan Yumuk, Constantine Tsigos, Martin Fried, Karin Schindler, Luca Busetto, Dragan Micic, Hermann Toplak. Obes Facts 2015
397
13

Health Effects of Overweight and Obesity in 195 Countries over 25 Years.
Ashkan Afshin, Mohammad H Forouzanfar, Marissa B Reitsma, Patrick Sur, Kara Estep, Alex Lee, Laurie Marczak, Ali H Mokdad, Maziar Moradi-Lakeh, Mohsen Naghavi,[...]. N Engl J Med 2017
13


The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
Anna Secher, Jacob Jelsing, Arian F Baquero, Jacob Hecksher-Sørensen, Michael A Cowley, Louise S Dalbøge, Gitte Hansen, Kevin L Grove, Charles Pyke, Kirsten Raun,[...]. J Clin Invest 2014
408
12


Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, George Abouda, Mark A Aldersley,[...]. Lancet 2016
838
12


A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
Caroline M Apovian, Louis Aronne, Domenica Rubino, Christopher Still, Holly Wyatt, Colleen Burns, Dennis Kim, Eduardo Dunayevich. Obesity (Silver Spring) 2013
271
11

Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Rohan Khera, Mohammad Hassan Murad, Apoorva K Chandar, Parambir S Dulai, Zhen Wang, Larry J Prokop, Rohit Loomba, Michael Camilleri, Siddharth Singh. JAMA 2016
316
11

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
W Timothy Garvey, Donna H Ryan, Michelle Look, Kishore M Gadde, David B Allison, Craig A Peterson, Michael Schwiers, Wesley W Day, Charles H Bowden. Am J Clin Nutr 2012
349
11



Glucagon-like peptide 1 (GLP-1).
T D Müller, B Finan, S R Bloom, D D'Alessio, D J Drucker, P R Flatt, A Fritsche, F Gribble, H J Grill, J F Habener,[...]. Mol Metab 2019
325
11

Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.
Priscilla Hollander, Alok K Gupta, Raymond Plodkowski, Frank Greenway, Harold Bays, Colleen Burns, Preston Klassen, Ken Fujioka. Diabetes Care 2013
216
10


Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
Arne Astrup, Stephan Rössner, Luc Van Gaal, Aila Rissanen, Leo Niskanen, Mazin Al Hakim, Jesper Madsen, Mads F Rasmussen, Michael E J Lean. Lancet 2009
634
10

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Christopher Sorli, Shin-Ichi Harashima, George M Tsoukas, Jeffrey Unger, Julie Derving Karsbøl, Thomas Hansen, Stephen C Bain. Lancet Diabetes Endocrinol 2017
190
10

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
Andrew J Ahmann, Matthew Capehorn, Guillaume Charpentier, Francesco Dotta, Elena Henkel, Ildiko Lingvay, Anders G Holst, Miriam P Annett, Vanita R Aroda. Diabetes Care 2018
195
10

The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.
Martin Friedrichsen, Astrid Breitschaft, Sayeh Tadayon, Alicja Wizert, Dorthe Skovgaard. Diabetes Obes Metab 2021
23
43

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Philip Ambery, Victoria E Parker, Michael Stumvoll, Maximilian G Posch, Tim Heise, Leona Plum-Moerschel, Lan-Feng Tsai, Darren Robertson, Meena Jain, Marcella Petrone,[...]. Lancet 2018
132
10

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Tamer Coskun, Kyle W Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B Bokvist, Xuewei Cui, Daniel A Briere, Over Cabrera, William C Roell,[...]. Mol Metab 2018
153
10

Multicenter, placebo-controlled trial of lorcaserin for weight management.
Steven R Smith, Neil J Weissman, Christen M Anderson, Matilde Sanchez, Emil Chuang, Scott Stubbe, Harold Bays, William R Shanahan. N Engl J Med 2010
590
9


Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
A Astrup, R Carraro, N Finer, A Harper, M Kunesova, M E J Lean, L Niskanen, M F Rasmussen, A Rissanen, S Rössner,[...]. Int J Obes (Lond) 2012
344
9

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén,[...]. Lancet 2019
806
9

A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.
Aaron S Kelly, Pernille Auerbach, Margarita Barrientos-Perez, Inge Gies, Paula M Hale, Claude Marcus, Lucy D Mastrandrea, Nandana Prabhu, Silva Arslanian. N Engl J Med 2020
93
9

Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial.
Thomas A Wadden, Jena Shaw Tronieri, Danny Sugimoto, Michael Taulo Lund, Pernille Auerbach, Camilla Jensen, Domenica Rubino. Obesity (Silver Spring) 2020
23
39

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Søren L Kristensen, Rasmus Rørth, Pardeep S Jhund, Kieran F Docherty, Naveed Sattar, David Preiss, Lars Køber, Mark C Petrie, John J V McMurray. Lancet Diabetes Endocrinol 2019
474
9

Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity.
Zachary J Ward, Sara N Bleich, Angie L Cradock, Jessica L Barrett, Catherine M Giles, Chasmine Flax, Michael W Long, Steven L Gortmaker. N Engl J Med 2019
412
9

Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.
A Blackman, G D Foster, G Zammit, R Rosenberg, L Aronne, T Wadden, B Claudius, C B Jensen, E Mignot. Int J Obes (Lond) 2016
128
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.